Skip to content

Prospective Lifespan Cohort of Myocardial Infarction

A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07471763
Enrollment
6000
Registered
2026-03-13
Start date
2026-04-10
Completion date
2031-04-10
Last updated
2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction (AMI), Stable Angina, Unstable Angina

Keywords

prospective cohort, multi-omics, artificial intelligence, risk prediction, precision medicine, acute myocardial infarction, lifespan cohort

Brief summary

This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management. The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up. The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.

Interventions

None listed

Sponsors

Fujian Provincial Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

Age 18 to 74 years Diagnosed with stable angina, unstable angina, or acute myocardial infarction For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction Willing to participate and able to provide written informed consent Able to complete baseline assessment, biospecimen collection, and long-term follow-up

Exclusion criteria

End-stage malignant tumor with expected survival of less than 1 year Severe hepatic or renal dysfunction (estimated glomerular filtration rate \<30 mL/min/1.73 m² or Child-Pugh class C) Active autoimmune disease or long-term use of immunosuppressive agents Pregnant or breastfeeding women Inability to provide informed consent or severe cognitive impairment Previous participation in another clinical study that may conflict with this project Any other condition considered by the investigators to make participation inappropriate

Design outcomes

Primary

MeasureTime frame
Rate of all-cause mortalityFrom enrollment to the end of study follow-up, up to 5 years

Secondary

MeasureTime frame
Rate of cardiovascular deathFrom enrollment to the end of study follow-up, up to 5 years
Rate of recurrent myocardial infarctionFrom enrollment to the end of study follow-up, up to 5 years
Rate of readmission due to heart failureFrom enrollment to the end of study follow-up, up to 5 years
Rate of target vessel or non-target vessel revascularizationFrom enrollment to the end of study follow-up, up to 5 years
Rate of strokeFrom enrollment to the end of study follow-up, up to 5 years
Rate of definite or probable stent thrombosisFrom enrollment to the end of study follow-up, up to 5 years
Rate of severe bleedingFrom enrollment to the end of study follow-up, up to 5 years

Countries

China

Contacts

CONTACTKaiyang Lin, PhD
lky7411@sina.com+86 13559355708
PRINCIPAL_INVESTIGATORKaiyang Lin, PhD

Fuzhou University Affiliated Provincial Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026